Zum Inhalt springen

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi has informed Kymera that it…

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Entdecke mehr von LabNews

Melde dich für ein Abonnement an, um die neuesten Beiträge per E-Mail zu erhalten.

Autoren-Avatar
LabNews Media LLC
LabNews: Biotech. Digital Health. Life Sciences. Pugnalom: Environmental News. Nature Conservation. Climate Change. augenauf.blog: Wir beobachten Missstände

Entdecke mehr von LabNews

Jetzt abonnieren, um weiterzulesen und auf das gesamte Archiv zuzugreifen.

Weiterlesen